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Abstract
Despite rapid progress in our understanding of disease mechanisms and an exploding list of new
targets for therapeutic intervention, drug discovery and development remains a highly risky
business. Understanding the risk involved requires appreciation of the differing perspectives of risk
held by the various stakeholders involved in drug research. Risk can be reduced by thoughtful
management of drug candidate selection, careful planning and program execution by a team of
engaged experts, and disciplined decision making. Drug development is particularly challenging for
treatments of neurodegenerative diseases such as Alzheimer's disease, in which translation from
animal models of efficacy to human success is poor or unknown, the timelines for clinical study are
long, and the markers of efficacy are still evolving. Despite this there are several therapies in clinical
development that hold the promise of influencing this disease through novel and possibly synergistic
mechanisms.
Introduction
Drug discovery and development is a risky business. It can
take decades to turn a new product concept into some-
thing of real value. Often commercial value is not realized
until the first evidence that the drug works in patients is
demonstrated, often referred to as the 'clinical proof of
concept'. Thereafter, additional millions of dollars of
investment are required to conduct the clinical trials nec-
essary to substantiate safety and efficacy claims for market
approval.
Approximately 11% of new drugs that enter clinical trials
make it to the US market [1]. For central nervous system
(CNS) drugs this rate is poorer than the average for all
drugs, with only about 8% becoming available to the US
public. Amplifying overall drug development risk is the
falling productivity in delivering new drug entities to the
marketplace [2]. This productivity decrease is occurring
despite a rapidly expanding base of potentially new tar-
gets for treating disease and quantum leaps in the num-
bers of compounds synthesized and screened using
combinatorial chemistry and high throughput methods.
Since 1993, spending on research and development has
increased more than threefold after adjusting for infla-
tion, whereas the numbers of new molecular entities
approved by the US Food and Drug Administration (FDA)
has fallen from 30 to 50 per year in the late 1990 s to
between 15 and 25 in recent years. In response, the FDA is
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providing leadership in re-evaluating how medical prod-
ucts are developed through the 'Critical Path Initiative'
[3]. Several joint industry-government projects have
started under this important initiative, and time will tell
whether this effort will have an impact.
In the face of these brutal facts about poor success rates
and dropping productivity, it seems essential that anyone
participating in the business of drug discovery and devel-
opment should be able to make decisions within a frame-
work that includes practical risk assessment. This paper
describes how risk is perceived (for instance, measured or
defined?), what affects risk, and proven ways to manage
risk, with commentary on drugs developed to treat neuro-
degenerative diseases.
Defining risk
Risk (the potential for loss or injury) in drug development
differs depending on which of several stakeholders you
ask. These varying perspectives can be broadly collected
into three views of risk: development investment risk, risk
to the patient, and risk for therapeutic failure.
Development investment risk is the primary focus of com-
pany managers and owners who are weighing the invest-
ment involved against the potential for success or failure.
Development investment risk depends not only on the
financial resources available but also on what expertise
can be engaged in the development of the drug, the regu-
latory requirements involved, and what other expecta-
tions exist for the product (for example, the time for
development).
Risk to the patient is of interest to all of the stakeholders
who are patient advocates in the process of drug develop-
ment, including the pharmaceutical companies, investiga-
tors, the institutional review boards, and government
regulators. Patient safety is the primary focus of FDA reg-
ulations, and approval is ultimately based on an argu-
ment of risk versus benefit or safety (injury) versus efficacy
(improved health). Other drugs the patient may be taking
that could interact, usually negatively, with the new drug
also affect patient risk. Finally, reimbursement costs may
determine who receives (or who is not willing or able to
pay for) the medication.
Closely related to both of the above perspectives is risk for
therapeutic failure. This is the focus of both investigators
and investors. Investigators want to study drugs that have
a reasonable chance of success in their patients. Investors
want to back something that works and will sell, even if
the chance of loss (risk) is high.
The one factor that has an impact on all three views of risk
is the novelty of the product. Novel products are less pre-
dictable, thereby enhancing risk to patient, investor, and
drug developer. There is no benchmark for clinical effect
with new targets, making it difficult to have confidence in
the animal models used in drug discovery screening.
Novel drugs require more education of regulators, institu-
tional review boards, and investigators before they feel
comfortable in participating in, or giving their approval
for, clinical studies. Finally, the marketplace is more leery
of novel products, despite their promise of better treat-
ment.
Strategies for managing risk in drug discovery 
and development
Mitigating risk is a matter of making informed choices.
Success involves selecting a good drug but then effectively
managing the entire development process for this drug.
The drug product will 'live or die' based on its inherent
properties. However, there are many opportunities for a
good drug to flounder because of poor product develop-
ment decisions, inadequate investment and planning, or
poor execution.
Pick a good drug
Determining which candidate to select for further drug
development from many leads can be challenging. Ide-
ally, the selected candidate should be better than other
known products that interact with the same target. If the
target is novel, then there must be sufficient confidence
and investment to prove the relevance of the novel target.
Part of the concept of 'translational medicine' emphasizes
the need for 'valid' animal models of disease. Validity can
be measured three ways. Most important in reducing over-
all risk is 'predictive validity', in which a drug that works
in the animal will work in humans. Current animal mod-
els for Alzheimer's disease (for example, β-amyloid toxic-
ity or rat memory impairment) have poor predictability.
By comparison, those for Parkinson's disease (6OHDA in
rat and MPTP in mouse or monkey) have relatively good
predictive validity, but suffer because they present a much
more acute pathology than the human disease. An animal
model can have 'face validity' when it mimics the signs
and symptoms of the human disease (for instance, mem-
ory loss in Alzheimer's disease). Finally, 'construct valid-
ity' can be claimed if the underlying pathophysiology of
the animal model is the same as in the human disease (for
example, β-amyloid toxicity in Alzheimer's disease, SOD1
G93A transgenic mice in amytropic lateral sclerosis).
Complementing the need for good animal models are the
important new biomarker tools for measuring effect both
preclinically and clinically that are emerging from an
expanding universe of technologies, which include imag-
ing, proteomics, genomics, and metabolomics. For neuro-
degenerative diseases, genetic testing for people who areBMC Neuroscience 2008, 9(Suppl 3):S1 http://www.biomedcentral.com/1471-2202/9/S3/S1
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at risk is informing the decision of who should be
enrolled in certain clinical trials for potential new treat-
ments of Alzheimer's disease, Parkinson's disease, and
amytropic lateral sclerosis [4]. Magnetic resonance imag-
ing and positron emission tomography imaging promise
noninvasive ways to track many diseases [5], including
the formation of neurofibrilary tangles and amyloid
plaques in patients with dementia. Cellular imaging tech-
niques are also being applied in drug discovery [6].
Over the past 15 years significant advances have been
made that help to pick molecules during discovery that
have the appropriate physiochemical properties to ensure
acceptable manufacture and formulation, as well as pre-
dictable pharmacodynamic/pharmacokinetic/ADME
(absorption, distribution, metabolism, and excretion)
properties in humans. In a 2000 survey, only 12% of
drugs that failed in the clinic during the preceding 10
years did so because of unacceptable pharmacodynamic/
pharmacokinetic/ADME properties, as compared with
nearly 50% recorded in a similar survey conducted in
1991 [1,5]. This is evidence that appropriate technology
applied to selection strategies in the discovery phase does
reduce risk of failure in the clinic.
In the past, 'Investigator INDs' (with IND meaning Notice
of Claimed Investigational Exemption for a New Drug)
were often used (and abused) as a way to get new drugs
introduced into patients quickly. Investigator INDs were
designed to promote clinical academic research in small
numbers of patients. Often, the results of such trials have
been difficult to interpret and usually provided messy
information for decision making. In 2005, the FDA
offered the 'Exploratory IND', as a way to give small, sub-
therapeutic doses of drug to humans without extensive
toxicology or Chemistry, Manufacturing, and Controls
documentation. This approach can offer early confirma-
tion of half-life or bioavailability in humans, or initial evi-
dence of efficacy, should the effect on some biomarker of
the target be measurable at subtherapeutic doses. The
exploratory IND offers a way to exploit emerging imaging
technologies and agents (for example, positron emission
tomography and magnetic resonance imaging) to assess
drug effects on disease or drug distribution into the CNS.
Once a drug candidate is selected, a conventional IND is
required for further clinical development; nevertheless,
the risk for therapeutic failure is reduced. The impact of
the exploratory IND on overall costs is a matter of debate
at this time.
Have a good plan
Drug discovery and development is a process that moves
through several 'go/no go' decision gates [7]. A good plan
evolves by determining the key questions that must be
answered before making the go/no go decision. Then,
studies are designed to address these specific questions. By
working backward through the process, all work done
between decision gates is rationalized, wasted effort
avoided, consensus built, and overall risk reduced.
Be disciplined about decision making
At each decision gate, it is important that everyone who is
key to the process understands and achieves consensus on
the following questions. What is the decision process
(directive, democratic, or consensus)? Who decides, con-
sults, or is informed of the decision? What are the choices?
By studying scenarios ahead of time, one builds confi-
dence in the decision strategy. Often, this is framed in
terms of criteria for deciding, examples being the success-
ful use of the 'target product profile' in drug development.
Involve the right people
Successful modern drug development is managed by a
team of committed people who represent needed exper-
tise and are led by a 'champion' for the project. The leader
educates decision makers and ensures priority and
resources for assigned work. Successful teams look for
synergy in their efforts built on mutual respect.
Execute well
Effective execution involves good project management
skills to ensure that work is done on time and on budget.
Moreover, every successful drug had a team that reacted to
unforeseen events in a timely and reasoned way through
open dialog that started with contingency planning.
Challenges facing development of CNS drugs
Compared with other therapeutic categories, CNS drugs –
particularly those targeted at neurodegenerative disease –
face certain unique challenges that add risk.
Evolving translational research
There are few predictive animal models of human neuro-
degenerative diseases, including Alzheimer's disease. Add-
ing to the complexity is that no single disease mechanism
has emerged as the dominant driver for the emergence
and progression of this disease. Recent legislation and
agreements requiring public disclosure of clinical trial
results, both positive and negative, should improve access
to human data. Extensive human information is required
before we know the translational power of animal models
to human experience. Over the next few years we will
learn from patients suffering from Alzheimer's type
dementia whether drugs that reduce β amyloid build-up
or block its neurotoxicity will outperform those that stim-
ulate neurotransmitter function, those that reduce inflam-
mation, and those that have neurotropic properties.BMC Neuroscience 2008, 9(Suppl 3):S1 http://www.biomedcentral.com/1471-2202/9/S3/S1
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Changing standards of care
It is likely that future therapies will involve a combination
of products that attack different features of the disease and
will hopefully work synergistically in providing relief
from the progression of Alzheimer's disease. This
approach is already being used as a standard of care in
many areas of the USA, where a cholinesterase inhibitor is
being prescribed together with memantine under the
belief that two therapies will be better than one. So far, the
practice is limited by tolerance issues in some patients, as
well as the patient's ability to pay for more than one phar-
maceutical treatment for their disease. Nevertheless,
multidrug therapy creates another challenge in designing
early clinical studies to determine whether new and novel
therapies are effective and safe. Most patients (and their
care givers) will not wish to be randomized to the risk for
being treated with no or limited treatment for long peri-
ods of time (3 months to 1 year), which is a defining
requirement for a statistically credible control group.
Therefore, we are forced to consider add-on trial designs.
By their nature, phase II studies involve a relatively small
number of patients (50 to 400) because it is usually not
prudent to invest in large clinical trials and drug manufac-
ture without some signal of efficacy. It can be very chal-
lenging under these circumstances to design a study with
sufficient statistical power to inform good decision mak-
ing. In addition, add-on designs place greater weight on
early consideration of potential drug-drug interactions.
Fortunately, there has been good progress in recent years
in the strategies and science surrounding early predication
of how one drug might affect the metabolism of another.
Biomarker development
Developing relevant biomarkers of effect is one way to
work around these issues and obtain clinical proof-of-
concept information more quickly. Unfortunately, no
biochemical markers in human plasma, serum, blood, or
urine have emerged as broadly accepted predictors of dis-
ease progression or as sensitive indicators of the effect of
therapeutic intervention on specific pharmacologic tar-
gets. Brain imaging technology holds the most hope and
is the focus of considerable current clinical research effort.
Often, CNS diseases progress in severity beyond a point of
effective intervention. However, people with mild disease
are difficult to identify. There is strong commercial and
academic interest in the development of early biomarkers
that can diagnose the presence of mild disease even before
behavioral and memory symptoms appear. Conversely,
patients with severe or refractory disease make poor trial
candidates.
Drug delivery to the brain
Delivering active drug past the blood-brain barrier can be
a challenge. Unless one has a long-acting drug product,
parenteral routes of administration would not be practical
in a typical Alzheimer's patient setting. A once-a-day oral
product that distributes readily to the site of action (CNS)
is the ideal; most currently marketed drugs for treating
Alzheimer's symptoms possess these features.
Competition for study participants
There are several new therapies that are currently in early
clinical trials as well as continued testing to optimize use
of currently marketed agents. However, despite an
expanding patient base, the intensity of clinical research
does mean that different studies and therapies are com-
peting for an increasingly limited pool of patients. Collab-
orative study designs involving two or three new drug
products may be the only practical solution that could
address the efficiencies and ethics of performing large
clinical trials in this area.
Unlike most other clinical drug development programs,
the study of treatments for neurodegenerative diseases
involves both the patient and their care giver. The addi-
tional challenge of relying on two different perspectives in
therapeutic assessment and study management cannot be
understated.
Conclusion
Risk management involves understanding the different
perspectives among stakeholders and making informed
choices. Keys to success are picking a good drug (although
the models and biomarkers may be less than 'good') and
then managing its development well. Modern drug dis-
covery techniques, properly applied, reduce the risk for
failure in the clinic and provide hope for better future
therapies for neurodegenerative disease.
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